Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Atacicept - Vera Therapeutics

Next Previous
Drug Profile

Atacicept - Vera Therapeutics

Alternative Names: Anti-Blys/anti-APRIL fusion protein - Vera Therapeutics; Atacicept-vymj - Vera therapeutics; BLyS/APRIL-heterotrimers - Vera Therapeutics; TACI-Ig; TRUTAKNA; VT-001

Latest Information Update: 09 Jul 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ZymoGenetics
  • Developer EMD Serono; Merck Serono; Vera Therapeutics; ZymoGenetics
  • Class Antineoplastics; Antirheumatics; Eye disorder therapies; Immunoglobulin Fc fragments; Immunotherapies; Recombinant fusion proteins; Urologics
  • Mechanism of Action B cell activating factor inhibitors; Tumour necrosis factor ligand superfamily member 13 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - IgA nephropathy
  • New Molecular Entity Yes

Highest Development Phases

  • Registered IgA nephropathy
  • Phase II Focal segmental glomerulosclerosis; Lipoid nephrosis; Membranous glomerulonephritis; Nephrotic syndrome
  • No development reported Lupus nephritis; Systemic lupus erythematosus
  • Discontinued Chronic lymphocytic leukaemia; Multiple myeloma; Multiple sclerosis; Non-Hodgkin's lymphoma; Optic neuritis; Rheumatoid arthritis

Most Recent Events

  • 09 Jul 2026 No development reported - Phase-II for Systemic lupus erythematosus in Brazil, Chile, Chile, Japan, Peru (SC) (Vera Therapeutics pipeline, July 2026)
  • 09 Jul 2026 No development reported - Phase-II/III for Systemic lupus erythematosus (In adolescents, In the elderly, In adults) in United Kingdom, Spain, Poland, Netherlands, Lithuania, Latvia, Germany, France, Czech Republic, Bulgaria, Austria, Ukraine, Taiwan, Switzerland, Serbia, Russia, Philippines, Mexico, South Korea, India, Lebanon, Croatia, Israel, Argentina, Malaysia, Australia, South Africa, Greece, USA (SC) (Vera Therapeutics pipeline, July 2026)
  • 08 Jul 2026 No development reported - Phase-II/III for Lupus nephritis (Combination therapy) in USA, Czech Republic, Malaysia, Singapore, Taiwan (SC)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top